Marie C Hupe1, M Raschid Hoda1, Friedemann Zengerling2, Sven Perner3, Axel S Merseburger1, Marcus V Cronauer4. 1. Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. 2. Department of Urology, University of Ulm, 89075, Ulm, Germany. 3. Pathology of the University Hospital Schleswig-Holstein, Campus Lübeck and Research Center Borstel, Leibniz Center for Medicine and Biosciences, Borstel, Germany. 4. Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. marcus.cronauer@uksh.de.
Abstract
OBJECTIVE: The bromodomain and extra-terminal (BET) family of proteins provides a scaffolding platform for the recruitment and tethering of transcription factors to acetylated chromatin, thereby modulating gene expression. In this study, we evaluated the efficacy of the BET-inhibitor PFI-1 to diminish AR/AR-V7 signaling and proliferation in castration-resistant prostate cancer cells. METHODS: Prostate-specific antigen and androgen receptor (AR) protein were quantified by means of two commercial ELISAs. Transactivation of the AR, AR-V7 and Q641X was determined by reporter gene assays. Cell proliferation was measured using a colorimetric MTT-assay. RESULTS: PFI-1 dose-dependently inhibited transactivation of full-length AR (non- mutated, i.e., wild-type or point-mutated/promiscuous forms) without affecting their cellular protein levels. Moreover, PFI-1 was active against C-terminally truncated constitutively active ARs like AR-V7 and Q641X. Prostate cancer cells exhibiting a transcriptionally active AR-signaling complex (LNCaP, 22Rv1) were more susceptible to the growth-inhibitory effects than the AR-negative PC-3 cells. CONCLUSION: The quinazolinone PFI-1 is a highly efficient inhibitor of AR-signaling-competent prostate cancer cells in vitro. PFI-1 could serve as a lead compound for the development of new therapeutics able to block AR/AR-V7 signaling in advanced prostate cancer.
OBJECTIVE: The bromodomain and extra-terminal (BET) family of proteins provides a scaffolding platform for the recruitment and tethering of transcription factors to acetylated chromatin, thereby modulating gene expression. In this study, we evaluated the efficacy of the BET-inhibitor PFI-1 to diminish AR/AR-V7 signaling and proliferation in castration-resistant prostate cancer cells. METHODS: Prostate-specific antigen and androgen receptor (AR) protein were quantified by means of two commercial ELISAs. Transactivation of the AR, AR-V7 and Q641X was determined by reporter gene assays. Cell proliferation was measured using a colorimetric MTT-assay. RESULTS: PFI-1 dose-dependently inhibited transactivation of full-length AR (non- mutated, i.e., wild-type or point-mutated/promiscuous forms) without affecting their cellular protein levels. Moreover, PFI-1 was active against C-terminally truncated constitutively active ARs like AR-V7 and Q641X. Prostate cancer cells exhibiting a transcriptionally active AR-signaling complex (LNCaP, 22Rv1) were more susceptible to the growth-inhibitory effects than the AR-negative PC-3 cells. CONCLUSION: The quinazolinone PFI-1 is a highly efficient inhibitor of AR-signaling-competent prostate cancer cells in vitro. PFI-1 could serve as a lead compound for the development of new therapeutics able to block AR/AR-V7 signaling in advanced prostate cancer.
Entities:
Keywords:
AR-V7; Androgen receptor; BET inhibitor; BRD4
Authors: Friedemann Zengerling; Anca Azoitei; Alexander Herweg; Florian Jentzmik; Marcus V Cronauer Journal: World J Urol Date: 2015-08-29 Impact factor: 4.226
Authors: Sarah Picaud; David Da Costa; Angeliki Thanasopoulou; Panagis Filippakopoulos; Paul V Fish; Martin Philpott; Oleg Fedorov; Paul Brennan; Mark E Bunnage; Dafydd R Owen; James E Bradner; Philippe Taniere; Brendan O'Sullivan; Susanne Müller; Juerg Schwaller; Tatjana Stankovic; Stefan Knapp Journal: Cancer Res Date: 2013-04-10 Impact factor: 12.701
Authors: Stefanie V Schütz; Andres J Schrader; Friedemann Zengerling; Felicitas Genze; Marcus V Cronauer; Mark Schrader Journal: PLoS One Date: 2011-09-29 Impact factor: 3.240
Authors: Axel S Merseburger; Peter Hammerer; Francois Rozet; Thierry Roumeguère; Orazio Caffo; Fernando Calais da Silva; Antonio Alcaraz Journal: World J Urol Date: 2014-09-27 Impact factor: 4.226
Authors: Dong Han; Shuai Gao; Kevin Valencia; Jude Owiredu; Wanting Han; Eric de Waal; Jill A Macoska; Changmeng Cai Journal: Oncotarget Date: 2017-01-24
Authors: Irfan A Asangani; Kari Wilder-Romans; Vijaya L Dommeti; Pranathi M Krishnamurthy; Ingrid J Apel; June Escara-Wilke; Stephen R Plymate; Nora M Navone; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan Journal: Mol Cancer Res Date: 2016-01-20 Impact factor: 5.852
Authors: Emmanuel S Antonarakis; Jun Luo; Andrew J Armstrong; Landon C Brown; Changxue Lu Journal: Prostate Cancer Prostatic Dis Date: 2020-02-24 Impact factor: 5.554